Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

NCT05430399 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

349

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: utidelone
DRUG: docetaxel

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]